April 5, 2024Cancer Research

Abstract CT212: Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

View Full Paper

Ask AI

Bookmark

Authors

KKKyu‐pyo KimUlsan College MSMariano Ponz SarviseClinica Universidad de Navarra TMTeresa MacarullaVall d'Hebron Hospital Universitari

Discussion

Member takes

Implication

Randomized trial demonstrates improved survival despite lower response rates in pancreatic ductal adenocarcinoma, suggesting dual adenosine blockade may confer clinical benefit.

Key Points

Adding etrumadenant and atezolizumab to chemotherapy did not improve objective response rate, but extended overall survival in metastatic pancreatic ductal adenocarcinoma.
Median overall survival reached 16.49 months with the triple combination compared to 12.12 months with chemotherapy alone, while objective response rate was lower.
Randomized open-label trial evaluation showed manageable safety without new toxicities, suggesting adenosine signaling inhibition warrants further clinical investigation.

Cite This Study

Kim et al. (2024) studied this question.

synapsesocial.com/papers/68e70461b6db64358767ea7e https://doi.org/10.1158/1538-7445.am2024-ct212

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates improved survival despite lower response rates in pancreatic ductal adenocarcinoma, suggesting dual adenosine blockade may confer clinical benefit.

Abstract CT212: Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract CT212: Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider